Gemina Laboratories Stock Today
| GLABF Stock | USD 0.55 0.01 1.79% |
Performance12 of 100
| Odds Of DistressOver 57
|
Gemina Laboratories is trading at 0.55 as of the 29th of November 2024. This is a 1.79 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.55. Gemina Laboratories has over 57 % chance of experiencing financial distress in the next 2 years of operation, but had a somewhat good returns during the last 90 days. Equity ratings for Gemina Laboratories are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 10th of December 2022 and ending today, the 29th of November 2024. Click here to learn more.
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. The company has 64.1 M outstanding shares. More on Gemina Laboratories
Moving against Gemina OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Gemina OTC Stock Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Gemina Laboratories [GLABF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with a current market capitalization of 33.65 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Gemina Laboratories's market, we take the total number of its shares issued and multiply it by Gemina Laboratories's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Gemina Laboratories classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 64.1 M outstanding shares.
Gemina Laboratories has accumulated about 2.95 M in cash with (3.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05.
Check Gemina Laboratories Probability Of Bankruptcy
Ownership AllocationGemina Laboratories has a total of 64.1 Million outstanding shares. Gemina Laboratories secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Gemina Ownership Details
Gemina Laboratories Risk Profiles
| Mean Deviation | 3.64 | |||
| Semi Deviation | 3.55 | |||
| Standard Deviation | 6.96 | |||
| Variance | 48.48 |
Gemina Stock Against Markets
Picking the right benchmark for Gemina Laboratories otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Gemina Laboratories otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Gemina Laboratories is critical whether you are bullish or bearish towards Gemina Laboratories at a given time. Please also check how Gemina Laboratories' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Gemina Laboratories without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
Gemina Laboratories Corporate Management
Elected by the shareholders, the Gemina Laboratories' board of directors comprises two types of representatives: Gemina Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gemina. The board's role is to monitor Gemina Laboratories' management team and ensure that shareholders' interests are well served. Gemina Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gemina Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Browning | Head Limited | Profile | |
| Brian Firth | Chief Officer | Profile | |
| Robert Greene | Chief Director | Profile | |
| Bsc BSc | Chief Sec | Profile |
Other Information on Investing in Gemina OTC Stock
Gemina Laboratories financial ratios help investors to determine whether Gemina OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Gemina with respect to the benefits of owning Gemina Laboratories security.